Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Collagen type XXI alpha 1 chain is a structural protein encoded by the COL21A1 gene. It is part of the fibril-associated collagens with interrupted helices (FACIT) family, which contribute to the organization and integrity of the extracellular matrix. Type XXI collagen is localized to tissues containing type I collagen, including blood vessel walls, and is important for maintaining structural stability within the extracellular environment. Alternative splicing leads to multiple transcript variants. Pathway links involve the integrin signaling pathway and collagen trimerization, with some disease associations to certain renal carcinomas. There are currently no known direct drug interactions or targeting therapeutic approaches for this collagen chain. If more specific structural or functional data are needed—such as domain architecture—the protein contains domains like von Willebrand factor type A and thrombospondin-like N-terminal domains, characteristic of collagen superfamily members.
Not applicable; no known drugs or direct pharmacological interventions targeting this protein
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Collagen type XXI alpha 1 chain (COL21A1).